Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III LT-02 add-on therapy versus placebo in mesalamine-refractory ulcerative colitis
NL-OMON42292Phase 3Not yet recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of phosphatidylcholine (LT-02) in autoimmune colitis (4 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Deep remission at week 12. Planned start Mar 2014; status: not yet recruiting.
02
Drugs
phosphatidylcholine (LT-02)
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON42292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42292.